Peptide CDMO Comparison: Bachem Market Position & Value Drivers

Peptide CDMO Comparison at a Glance

Market-share figures vary by market definition, and this comparison is research-only, drawing on public filings and trade reporting rather than a commissioned benchmark.

How Should You Evaluate Technical Breadth?

Technical breadth is the ability to synthesize and characterize a difficult sequence, not the number of amino acids a brochure claims. Practical synthetic length is limited to roughly 50 to 70 residues because truncated sequences and impurities accumulate as the chain grows; beyond that, solid-phase synthesis and solution-phase fragment condensation are combined to reach longer or harder targets (Neuland Labs, 2025-07-31).

That limit matters because coupling-derived truncations accumulate exponentially with length, and impurities that are negligible at milligram scale become material at multi-kilogram scale. Aggregation and misfolded forms must be detected, and purification has to be re-developed for the larger batch (Neuland Labs, 2025-07-31). This is the failure mode that separates a supplier’s real technical depth from its marketing.

Bachem’s disclosed network spans Bubendorf, Sisslerfeld, Vionnaz, Vista, Torrance and St. Helens, with capability tiers deliberately differentiated by site. Its own half-year disclosure describes Vista as expanding high-volume capacity while Western Switzerland investments are aimed at securing key precursors, meaning some capital spending buys precursor security rather than API capacity (Bachem, 2026-07-30).

Specialist CDMOs compete on a different axis. The modification checklist a specialist publishes covers cyclic, disulfide-rich, stapled, PEGylated, lipidated, glycosylated and D- or unnatural-residue-enriched sequences, with cyclisation modes including head-to-tail, side-chain-to-side-chain and hydrocarbon stapling, plus an orthogonal Mga Sintetikong Peptide analytics set of LC-UV, LC-MS/HRMS with intact-mass deconvolution, peptide mapping, chiral and epimer ratio assays, and NMR for macrocycle or disulfide connectivity (Alfa CDMO, 2025-12-25).

A large integrated supplier usually wins on breadth of registered scale. A specialist can win on a single exotic modification. Breadth is therefore a portfolio question, not a size question, and it belongs near the top of any peptide supplier evaluation criteria.

Which Supplier Has the Stronger Quality Systems?

Quality systems are inspectable, not aspirational, so the comparison here is between records rather than reputations. The enforcement backdrop is tightening: the FDA issued 303 drug and biologics Warning Letters in FY2025 against 190 in FY2024, for-cause inspections of human drug and biologics sites ran roughly 250% above baseline in 2025, and quality-control unit responsibilities have been the top cited inspection issue for a fifth consecutive year. Directional reporting also suggests around 30% of Warning Letters to Chinese API facilities since 2024 contained data-integrity findings, though no denominator was published with that figure.

Most of those failures are contractual before they are technical. The quality-agreement gaps FDA cites trace back to 21 CFR 211.22(a) and (d): no formal quality agreement, responsibility assigned to “both parties” so nobody owns deviation investigation or batch release, manufacturing activities left unenumerated, change control undefined, and supplier certificates of analysis accepted without verification. Sponsors close that gap by demanding unredacted lot-specific CoAs, multi-lot purity and related-substance trend data, a quality agreement covering change control, deviation closure and audit rights, and the identity of the actual manufacturing site and line rather than a corporate summary.

Bachem’s own disclosure that Building K ramp-up costs compressed H1 2026 operating results, covered in trade reporting on Bachem’s expansion programme, is a transparency signal worth weighing. Scale alone proves nothing: one published supplier scorecard flags utilisation above 85% with no expansion plan and CAPA backlogs beyond 90 days, meaning corrective and preventive action queues that stall, as risks that apply to any supplier regardless of size. The supplier that shows you its deviation and CAPA data wins, and that is a question you ask, not a claim you read.

Does Announced Capacity Equal Qualified Capacity?

Announced reactor volume is not qualified capacity, and the gap between the two is where programs slip. An industry capacity tally puts global peptide API utilisation at 87–91% in 2026 against a sustainable long-run average of 70–75%, which means the constraint is real before any new build is counted (peptidestaff capacity-expansion analysis, retrieved 2026-09-18). The same tally estimates 18–36 months for large-scale SPPS capacity, 14–22 months order-to-delivery for synthesis equipment, and 18–24 months to qualify industrial-scale lyophilizers, with bulk new capacity commercially available only in 2027–2029.

Bachem’s own half-year disclosure draws the distinction cleanly: Building K was “successfully put into operation in 2026,” commercial GMP products have already been manufactured there, and the facility “is being gradually expanded to provide additional capacity” (Bachem ad-hoc release, 2026-07-30). That is operating capacity, not a projection. Trade reporting on Bachem’s expansion programme shows the network capex spanning Bubendorf, Sisslerfeld, Vionnaz, Vista, Torrance and St. Helens, with Bubendorf focused on reducing specific bottlenecks plus an operational initiative to unlock capacity by optimising utilisation of existing buildings (Pharma Manufacturing, 2026-07-31).

The forward pipeline is longer-dated. The Sisslerfeld announcement commits more than CHF 500m to a first phase with production expected by 2030 (Bachem ad-hoc release, 2026-07-30), and trade reporting puts total potential investment there above CHF 1.2bn with additional partners (Pharma Manufacturing, 2026-07-31). Across the sector, announced peptide CDMO capacity investments reached roughly $2.4bn year-to-date 2026 through the first five months, an industry capacity tally rather than an audited figure (peptidestaff capacity-expansion analysis, retrieved 2026-09-18).

A supplier with no new build can still win on near-term availability if it has optimised existing lines, so announced spend is a weak proxy for what you can actually book. Ask what is qualified today, what is qualified in twelve months, and what is a press release.

How Much Customization Should You Expect?

Customization means the supplier can change route, scale, presentation and analytics without renegotiating the relationship. In practice, that breaks into two very different questions, and knowing which one you are asking is the core of any peptide supplier evaluation criteria.

The first is chemistry. A specialist will enumerate the modification classes and cyclisation modes it can execute, and the analytics that prove them: LC-UV, LC-MS/HRMS with intact-mass deconvolution, peptide mapping, chiral and epimer ratio assays, and NMR for macrocycle or disulfide connectivity, as set out in the modification checklist a specialist publishes. The second is process. Purification steps such as preparative HPLC and continuous chromatography must be re-developed at scale, which is why synthesis scale-up fails on the downstream side far more often than on the resin.

Bachem’s own half-year disclosure describes a site-differentiated model, so customization there is partly a routing question: which site, which line, which precursor supply. Specialists compete instead on bespoke route design for a single hard sequence.

The nuance matters. For a standard GLP-1 sequence, customization is mostly commercial, a matter of slots, timelines and documentation. For a stapled or lipidated analogue, it is the whole decision.

Verdict: match the customization question to your molecule class before you compare suppliers at all.

How Responsive Is Each Supplier in Practice?

Responsiveness is the one peptide supplier evaluation criterion almost none of the public record covers. It shows up in tech-transfer timelines, deviation-closure times and change-control turnaround, and those numbers live in quality agreements, not in annual reports or press releases. What is public is the failure mode: the quality-agreement gaps FDA cites, where change control, deviation closure and audit rights were never pinned down in writing, are the same gaps that escalate into inspection findings.

Structurally, a large integrated supplier offers more parallel workstreams but more handoffs between them; a specialist shortens the decision chain but runs fewer functions at once. Both degrade at peak utilisation, and 2026 is a peak-utilisation market, so reference calls taken today describe a supplier under different load than the one you will actually work with.

Note: No public source in this comparison discloses deviation-closure or tech-transfer timelines. Score this criterion from your own audit and tech-transfer experience, not from a supplier’s references.

What Does the Pricing Picture Actually Show?

For a typical GMP peptide program, price is now set by capacity scarcity rather than by supplier efficiency. Reported pricing pressure in GLP-1 peptide API has pushed contract-manufacturing prices up 25 to 40 percent since 2023, while non-GLP-1 peptide API rose a milder 8 to 15 percent (market pricing analysis, retrieved 2026). The same source puts Chinese CDMO quotes 30 to 50 percent below Western suppliers for non-GLP-1 work and at 35 to 50 percent of Western prices for GLP-1, though it is an aggregator estimate with no disclosed methodology, and the widely repeated 15 to 25 percent band does not appear on the source page.

Bachem’s own half-year disclosure shows the reference supplier absorbing expansion cost rather than passing it through cleanly: H1 2026 EBITDA margin came in at 25.4 percent against 29.1 percent a year earlier (Bachem half-year report, 2026). That compression tracks the company’s 2026 guidance of CHF 350 to 400 million in capital expenditure, CHF 148.4 million of it already invested in H1 2026 (Bachem 2026 guidance, 2026). A peptide CDMO comparison built on price per gram therefore misses where the money actually goes.

The cheapest quote carries the highest qualification cost when the site, line or data package is unclear. Migration, re-qualification and add-on analytics can erase the headline gap entirely.

Verdict: compare total cost of qualification, not price per gram.

Who Should Choose Which Supplier?

If your molecule is a standard sequence at commercial scale, choose the supplier with qualified near-term capacity. If your molecule is a modified or hard-to-synthesize analogue, choose the supplier that can show you a comparable route and its analytics. That single split rule carries most of the decision.

Clinical-stage biotech with a modified peptide: prioritize route demonstration over scale promises. Ask for a comparable analogue, its impurity profile, and the analytics used to characterize it, because the modification classes that complicate synthesis are exactly where process fit matters most (the modification checklist a specialist publishes).

Commercial-stage sponsor needing multi-hundred-kilogram supply: weight qualified capacity above headline announcements. Announced reactors and released lots are different things, and the gap between them is where timelines slip (Bachem’s own half-year disclosure shows how the company itself separates site capability tiers).

Sponsor diversifying away from a single-site dependency: treat tech transfer as a cost line, not a formality. Re-qualification, analytical method transfer, and regulatory filings all restart when the site changes (why synthesis scale-up fails documents the failure modes).

Academic or early-discovery group: optimize for route flexibility and small-batch access rather than commercial capacity.

When neither a large integrated supplier nor a specialist fits, the answer is usually dual-sourcing: use the criteria above as the split rule, assigning each program to the supplier that wins its dominant dimension. A documentation-oriented evaluation workflow, such as the one MOL Changes describes, can help you score peptide supplier evaluation criteria consistently across candidates before you commit.

If you are weighing two shortlisted suppliers, compare their capabilities against your own program’s constraints before the next batch decision.

Frequently Asked Questions

Is Bachem the best peptide CDMO?

No single supplier is best across every criterion, and the honest answer depends on which of the five evaluation dimensions your program weights most heavily. Bachem’s market position is strongest on quality systems and regulatory documentation depth, which matters most for late-phase and commercial programs. A specialist supplier can be the better fit when your sequence needs unusual chemistry or when you need responsiveness on a smaller program. Treat this as a peptide CDMO comparison driven by your own program profile, not a ranking.

Can we switch peptide CDMOs mid-program?

Yes, but the cost sits in the transfer, not the decision. Moving a program means re-establishing the synthesis route at the new site, transferring and re-validating analytical methods, and re-qualifying the supplier’s processes against your specification. That work is the same reason why synthesis scale-up fails when a route is locked too early: the chemistry, not the paperwork, is usually what resists transfer. Budget the effort before you commit to the move.

Can we use two peptide CDMOs at the same time?

Yes, and dual-sourcing is common, but the split matters. The usual pattern separates precursor supply from final API manufacture, which Bachem’s own half-year disclosure describes as part of how it manages capacity across sites. Splitting at the precursor stage keeps the regulated final step with one qualified supplier while adding a second source upstream. Splitting the API step itself across two sites multiplies your comparability and change-control burden.

Which criterion matters most for a modified peptide?

Technical breadth and customization carry the most weight once your sequence leaves standard chemistry. Non-natural residues, cyclization, conjugation and unusual modifications narrow the field quickly, because not every supplier’s platform handles them at scale. Work through the modification checklist a specialist publishes against each candidate’s stated capabilities before you weigh price or timeline.

Does announced 2026 capacity change the near-term picture?

Not much. New peptide CDMO capacity is largely a 2027 to 2030 story: the Sisslerfeld announcement places additional production at the end of that window, and an industry capacity tally shows bulk of the new build landing 2027 to 2029. For programs that need qualified capacity in the next twelve to eighteen months, scarcity is the operating condition, not a temporary blip.

Verdict: Where Each Supplier Type Wins

The decision rule from the opening holds after the analysis: choose the large incumbent when your program needs the deepest regulatory record and the widest qualified capacity, and choose a specialist when your sequence demands a non-standard route or your timeline demands a direct line to the people doing the work. The nuance worth naming is that these are not permanent positions. A specialist that adds a second site and a mature deviation history starts winning categories it currently loses, and an incumbent that reorganizes around a platform it already owns can close the customization gap faster than its size suggests.

One published supplier scorecard weights quality consistency at 30 to 40 percent and capacity transparency at 20 to 30 percent, with technical depth and customer outcomes filling the remainder, which is a useful reminder that no single category decides the outcome (one published supplier scorecard). Read the table as a starting position, not a scoreboard.

Next step: Compare capabilities against your own sequence and stage. If you want a second opinion on which dimensions actually carry weight for your program, talk to a technical expert before you send out the next request for proposal.

Disclosure: this comparison is published by MOL Changes, a peptide CDMO. Market-share figures cited in this article vary by market definition and should be read as ranges rather than fixed positions.